Alluvi, formerly BI 4744, represents a notable development in obesity therapy. This dual stimulator targeting both GLP-1 and GIP sites demonstrates remarkable effectiveness in patient trials, possibly outperforming https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/